(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.

Broadcom Slides After AI Chip Forecast Underwhelms Investors
20:57

Chevron to Invest $7 Billion to Double Its Venezuelan Output
23:39

Apple’s Ternus Takes Reins as CEO With AI a Priority
26:54